Trading-Depotwettbewerb USA Eröffnung 6,7 KW

So, das erste 2 Wochendepot ist fertig. Ich hatte mal wieder enorme Schwierigkeiten aus
mindestens 50 Superstocks auzuwählen.
Auf der Strecke blieben HITK, SCSS, die kleine Sandanta aus Kanada (SAND),DAKT, EXAC, Packeteer, SCSS, FLML, GRB, ORB ,MSN, MUSE, USNA, OPSW, Biomarin Pharma, La Jolla Pharma, und und und...

Wie schon gesagt, gefälllt mir auch Gruenis neues Depot ganz hervorragend, es gibt einfach zu viele auffällig gute Aktien in den USA.
Deshalb hab ich aus Spass keine Aktie aus anderen Depots gewählt.

Wichtig war für mich ebenfalls, dass alle Stocks die ich gewählt habe, bereits Zahlen gemeldet haben, von daher keine grössere Gefahr drohen sollte.
Einzige Ausnahme bei mir ist ATRX, sieht aus wie ein fallendes Messer, ist aber hoffentlich total überverkauft.

Leider haben sich Pavian und zick zock bis jetzt nicht gemeldet, legen wohl eine Pause ein, so dass die rote Fässchen Fraktion am aktivsten ist...

Nach den zwei Wochen stehen bestimmt alle Depots besser da, als am 31.01.02, da bin ich sehr zuversichtlich.

Gruss E.



 

einfach ein wenig Glück dazu, und nen enger SL.

Greetz f-h

Bin davon überzeugt, daß Du in 4 Wochen nicht mehr auf der neg. Seite stehst, viel Erfolg.  

Dann bin ich einfach zu doof zum RECHNEN und LESEN.

Ich hab mir ja deswegen auch 3 Querstriche mit `nem senkrechten Strich durch auf dem Arm tätowiert.

Datt heisst, ich kenne eine Person, die LESEN, RECHNEN und SCHREIBEN kann.

Teile dann bitte die Differenz zu gleichen Teilen auf meine 6 Werte auf.


                            Gr.Gr.;-)

                             


 

noch, dann könnte ich mich wieder ans Werk machen.
Pavian ist wieder an Bord, sehr gut. patzjeschniki dürfte auch gerne einsteigen, beschäftigt sich ja auch intensiv mit Ami-Stocks.

Also der frustrierte estrich sollte wieder einsteigen, hat einfach nen bisschen Pech gehabt, und seine SLs zu niedrig angesetzt. Nur seine Stocks interessieren mich weiterhin. Habt Ihr seine alten EMA in die WL aufgenommen, for example?

Gruss E.  

ZiZo hatte glaube ich schon letzte Woche was reingestellt, weiß allerdings nicht, ob das noch aktuell ist.

Greetz f-h  

Der One-day-Stop-close. Wer möchte, kann einen Stock auf Schlusskursbasis verkaufen, um einen Gewinn mitzunehmen.
Ich mache das, weil das Spiel dem Know-How vieler Spieler nicht gerecht wird.
Gruenis DHB waren in der letzten Runde schon 30% im Plus, meine FORD auch, jetzt wanderten diese mit Verlust aus dem Depot.
Wer also meint, einen Gewinn einstreichen zu wollen, darf auf Schlusskursbasis verkaufen
und eventuell höheren Kursen hinterhertrauern.
Gibt dem Spiel noch mehr Würze meine ich.
Für den verkauften Stock verbleibt allerdings Cash bis zur nächsten Runde im Depot. Gleich danach eine neuen Wert aufzunehmen ist nicht möglich.

Gruss E.


 

SSTI  3890 Stück   zu 2.57  $    =  9997.3 $     Stop 2.29 $

INEI  28000 Stück  zu 0.35 $     =  9800.0 $     Stop 0.27 $

RDTA  5000  Stück  zu 1.93 $     =  9650.0 $     Stop 1.53 $

AVNX  10000 Stück  zu 0.80 $     =  8000.0 $     Stop 0.74 $



GOLD raus und BGO dürfte ausgestoppt sein.



Grüße        Reiny



 

Da dürfte die Depots bald anders ausschauen.





Grüße          Reiny  

Mögl. Verkäufe unter den Tagen werden von mir auf SK- Basis jeweils kurz nach 22:00 hier angezeigt.

                                  Gr.Gr.  

Auf meinem Webspace sind sie noch, warum sehe ich sie hier nicht mehr?
Seltsam, na hoffentlich erscheint die neue Eröffnungs-Tabelle für die 8,9 KW vernünftig.

Gruss E.  

ich sehe hier die Tabellen und mein Verliererdepot noch.
;-(((

PS: Gerade nochmal in den Nachrichten gehört:

          Die Amis greifen nicht vor März an!
               
                     Der Bericht von Blix am 01.03.03 wird auf jeden Fall abgewartet.


     Bis dahin sind hier und im echten Aktien- Leben bestimmt Prozente zu holen!


                               Gr.Gr.

 

Microsoft implementiert Sinas SMS-Software in MS Office    
 
Microsoft hat am Freitag eine Kooperation mit dem in Hongkong ansässigen Softwareunternehmen Sina bekannt gegeben. Sina wird dabei sein SMS-System für MS Office XP Benutzer zur Verfügung stellen. Damit ist es möglich, Daten direkt aus Microsofts Büroanwendung heraus an Empfängerhandys zu versenden.

Dazu sollen beispielsweise Termine gehören. Die SMS-Kernfunktion wird wohl in Microsoft Outlook integriert werden, der Messaging-Software innerhalb von Office XP.

Die Aktien von Sina werden auch an der Nasdaq notiert und können am Freitag im späten US-Handel um 14,6 Prozent auf 6,65 Dollar hinzugewinnen. Microsoft notieren ein Prozent höher.

Grusse E.


 

haste mal kein Glück, kommt auch noch Pech dazu.Habe vor 14 Tagen MCLD zu 0.62 verkauft,heute stehen sie bei 0.84.
Ich mache mal ein bisschen tabula rasa: BVSN,MNG und Roxi fliegen raus-Gesamterlös 24642.66. Dafür kommen:
7200 MCLD (0.84)        6.084,--
1000 Sina (6.87)        6.087,--
500  Nvda(12.04)        6.020,--
15k  KAIR (0.38)        5.700,--
683  Avan (1.10)          751.30
Avan werde ich sukkzessive Aufstocken bis April.

Eskimato,nochmal lieben Dank für die Mühen.
Dem Rest einen schönen Sonntag.
Ciao B.L.  

XM Satellite Radio Holdings Inc. surged $1.30 to $5.07. The subscription radio service may prosper as conventional radio station formats begin to sound the same and listeners struggle to find their favorite music while avoiding an endless stream of commercials, Barron's said. Bloomberg News provides programming to XM and rival Siris Satellite Radio Inc. Sirius rose 25 cents to $1 and was the most active stock in early trading.
 

Wow, was für ein Schock, ob das passt?

Gruss E.

La Jolla Pharmaceutical Announces Conference Call to Discuss Phase III Results of Riquent for Lupus Renal Disease

SAN DIEGO, Feb 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that the Company will host a conference call to discuss the results of its Phase III clinical trial of Riquent(TM), formerly LJP 394, for the treatment of lupus renal disease. The conference call will take place today, Tuesday, February 18, 2003, at 4:30 p.m. Eastern Time. The dial in number is (800) 299-6183 for U.S. callers and (617) 801-9713 for international callers. The call identification number is 442218. A live audio webcast of the conference call will be available through La Jolla Pharmaceutical's Web site at www.ljpc.com .

La Jolla Pharmaceutical President and CEO, Steve Engle, and members of the senior management team will join the conference call.

The webcast will also be available to both institutional and individual investors via CCBN's Investor Distribution Network. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents, at www.streetevents.com .

A replay of the conference call can be accessed by dialing (888) 286-8010 (US) or (617) 801-6888 (International). The passcode for the replay is 08202838. The call will be available until Tuesday, February 25th. The call will also be available on the Company's website for the same period of time. If you are unable to access the conference call and would like additional information, please contact Cynthia Reindal, Manager of Investor Relations and Corporate Communications for La Jolla Pharmaceutical, at (858) 597-5542.

La Jolla Pharmaceutical Company is a biotechnology company developing therapeutics for antibody-mediated autoimmune diseases afflicting several million people in the United States and Europe. The Company is developing Riquent(TM), formerly known as LJP 394, for the treatment of lupus kidney disease, a leading cause of sickness and death in patients with lupus. The Company is also developing LJP 1082 for the treatment of antibody-mediated thrombosis, a condition in which patients suffer from recurrent stroke, deep- vein thrombosis and other thrombotic events. The Company's common stock is traded on The Nasdaq Stock Market under the symbol LJPC. For more information about the Company, visit our Web site: http://www.ljpc.com .

Except for historical statements, this press release, and the statements of management made during the above-referenced conference call, contain forward-looking statements involving significant risks and uncertainties, and a number of factors, both foreseen and unforeseen, could cause actual results to differ materially from our current expectations. Forward-looking statements include those which express a plan, belief, expectation, estimation, anticipation, intent, contingency, future development or similar expression. Although we expect to meet with the U.S. Food and Drug Administration ("FDA") to discuss the results of our Phase III trial of Riquent, there is no guarantee that a meeting with the FDA can be held in a timely manner, or at all, or that our meetings with them will result in us being able to continue to develop Riquent. Our analyses of clinical results of Riquent(TM), previously known as LJP 394, our drug candidate for the treatment of systemic lupus erythematosus ("lupus"), and LJP 1082, our drug candidate for the treatment of antibody-mediated thrombosis ("thrombosis"), are ongoing and future analyses could result in a finding that these drug candidates are not effective in large patient populations, do not provide a meaningful clinical benefit or may reveal a potential safety issue requiring us to develop new candidates. Our blood test to measure the binding affinity for Riquent(TM) is experimental, has not been validated by independent laboratories, may require regulatory approval, and may be necessary for the approval and the commercialization of Riquent(TM). Our other potential drug candidates are at earlier stages of development and involve comparable risks. Analysis of our clinical trials could have negative or inconclusive results. Any positive results observed to date may not be indicative of future results. In any event, the FDA may require additional clinical trials, or may not approve our drugs. Our ability to develop and sell our products in the future may be affected by the intellectual property rights of third parties. Additional risk factors include the uncertainty of: obtaining required regulatory approvals, including delays associated with any approvals that we may obtain; FDA approval of our manufacturing facilities and processes; the increase in capacity of our manufacturing capabilities for possible commercialization; successfully marketing and selling our products; our lack of manufacturing, marketing, and sales experience; generating future revenue from product sales or other sources such as collaborative relationships; future profitability; our need for additional financing; and our dependence on patents and other proprietary rights. Readers are cautioned to not place undue reliance upon forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date hereof. Interested parties are urged to review the risks described in our Registration Statement on Form S-3, filed December 10, 2002, our Annual Report on Form 10-K for the year ended December 31, 2001, and in other reports and registration statements that we file with the Securities and Exchange Commission from time to time.

SOURCE La Jolla Pharmaceutical Company

Cynthia Reindal, Manager of Corporate Communications and
Investor Relations of La Jolla Pharmaceutical Company, +1-858-597-5542

http://www.streetevents.com


 

Lajolla stürzt ab wegen fehlgeschlagenem PhaseIII Versuch bei dem von 500 Leuten mit Lupus 285 im Placeboversuch keinen Unterschied zeigten-das Risiko der Biotechfirmen!  

La Jolla Pharma stellte heute negative Daten für das Medikament Riquent vor, dass zur Behandlung der Autoimmunkrankheit Lupus diene. La Jola Pharma Aktien brechen zur Stunde um 72.19% auf $2.10 ein. Die Analysten von Fulcrum veröffentlichten eine Researchmitteilung, in der sie das Unternehmen verteidigen.

Die Ergebnisse für das Medikament seien nicht so schlecht, wie dies der Kursrückgang vermuten liese, so die Analysten von Fulcrum. Das Medikament diene zur Behandlung einer bislang nicht sinnvoll therapierbaren Krankheit, hieß es. Auch habe das Testverfahren keine Sicherheitsrisiken des Medikamentes aufgezeigt. Sollte ein weiterer Testdurchlauf von Nöten sein, so wird dies vom Unternehmen finanziert werden können, so Fulcrum weiter. Die Analysten haben ein Kursziel von $26.


Hab mir welche reingelegt...

Grüße
Pavian  

Waren bei mir im Depot, siehe oben, leider ausgestoppt.
ATRX hat es wohl gepackt, Zulassung ist da, hätten se ruhig 5 Tage eher bringen können.

Gruss E.

20.02.2003 - 10:40 Uhr
MediGene-Partner Atrix erhält Zulassung für Krebsmittel
München (vwd) - Die Atrix Laboratories Inc, ein Partner der MediGene AG hat in den USA die Zulassung für das Medikament Leuprogel gegen Prostatakrebs erhalten. Damit haben sich nach Einschätzung von MediGene die Zulassungschancen für Deutschland und Europa, wo das Unternehmen die exclusiven Vermarktungsrechte hält, erhöht. "Die europäischen Zulassungsanträge aller Leuprogel-Produkte basieren auf den bei der US-Behörde eingereichten Daten", erklärte MediGene-Vorstandsvorsitzender Peter Heinrich am Donnerstag in München.

Die Zulassung erfolgte für das Medikament mit einem Viermonatsdepot nachdem das Präparat mit Einmonats- bzw Dreimonatsdepot bereits 2002 in den USA eingeführt worden war. Die Zulassung der ersten Leuprogel-Produkte für den europäischen Markt erwarte MediGene im laufenden Jahr, hieß es weiter Das Medikament soll dann über einen Partner vertrieben werden. Die Umsätze mit vergleichbaren Medikamenten gegen Prostatakrebs lagen in Europa im Jahr 2001 den Angaben zufolge bei rund 600 Mio EUR. In den USA ist das Krebsmittel unter dem Namen "Eligard" bekannt.
vwd/20.2.2003/rne/mim

 
Meldung  
 

Gruss E.

FDA Approves Eligard(R) 30mg (Leuprolide Acetate for Injectable Suspension), Four-Month Prostate Cancer Product -- Approval Provides Full Market Participation -- Third NDA Approval in Thirteen Months -- Company Provides Information on Fourth Quarter/  


FORT COLLINS, Colo., Feb 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- Atrix
Laboratories, Inc. (Nasdaq: ATRX) announced today that the company has received
approval from the U.S. Food and Drug Administration (FDA) for Eligard(R) 30mg
(leuprolide acetate for injectable suspension), for the palliative treatment of
advanced prostate cancer. Similar to the other Eligard products, this approval
came 10 months from submission.

Eligard approval

This approval, along with the approvals of both Eligard 7.5mg one-month and
Eligard 22.5mg three-month prostate cancer products, means that the Eligard
product line now has the opportunity to compete in the entire $1 billion U.S.
hormone therapy market opportunity for hormone-sensitive prostate cancer.
Eligard 30mg will be marketed in the U.S. by Sanofi- Synthelabo (NYSE: SNY).
Sanofi-Synthelabo currently markets Eligard 7.5mg and Eligard 22.5mg in the U.S.

"A third FDA approval in 13 months clearly demonstrates the world-class skill
and expertise of the Atrix team," said David R. Bethune, Atrix's chairman and
chief executive officer. "Sales of the first two Eligard products are increasing
month-to-month and we expect further reorders in the coming months. The approval
of Eligard 30mg now enables the franchise to compete in the complete U.S.
marketplace. Almost half of the total $1 billion market for prostate cancer
hormone therapy consists of the four-month product. With the near-term launch of
Eligard 30mg, we now have the opportunity to begin to understand the real
adoption cycle for these products."

Sustained levels of leuprolide decreases testosterone levels to suppress tumor
growth in patients with hormone-responsive prostate cancer. The liquid Eligard
products are injected subcutaneously with a small gauge needle, forming a solid
implant in the body that slowly releases leuprolide as the implant is
bioabsorbed.

Eligard 30mg, like other hormonal treatments for prostate cancer, causes a
transient increase in serum concentrations of testosterone during the first week
of treatment. Patients may experience worsening of symptoms or onset of new
signs and symptoms during the first few weeks of treatment. Response to Eligard
30mg should be monitored by measuring serum concentrations of testosterone and
prostate specific antigen periodically.

Fourth Quarter

The company also estimates 2002 fourth quarter losses will be between $0.28 -
$0.32 per share and a full year 2002 loss in the range of $0.96 - $0.99 per
share.

Brian Richmond, Atrix's chief financial officer commented, "Issues impacting the
fourth quarter 2002 were primarily based on timing of the Eligard launch and
adoption. Also, we have increased R&D spending relating to the Atrisone(TM)
Phase III trials and also incurred one-time expenses due to the establishment of
a sales force in Germany for the direct marketing of Atridox(TM). We believe
that these expenses are investments in the future. Comparing year-to-year
financials, we continue to exhibit consistent revenue growth. For the year-ended
2002, we estimate a 70-75% increase in total revenue compared to total revenue
for the year-ended 2001. Based on current trends in revenue growth, particularly
with respect to Eligard, we remain on track in 2003. We project R&D spending to
grow moderating within a range of $35 - $39 million, focusing the majority of
our R&D budget on near-term value drivers including Atrisone(TM) and the
extended-release Eligard 45mg product.

The company believes that results for 2003 will be affected by a number of
factors including the approval of products, the ramp up in sales of the Eligard
product line, sale of Atridox in Europe and the U.S., and specific R&D
expenditures, other international and national economic trends, conditions and
other factors.

About Atrix Laboratories, Inc.


 

 

Konnte nicht anders sein verflucht. Ich hab grad ne Krise, mache einen Spaziergang durch die Sonne.

Gruss E.  

die Chancen kommen jeden Tag auf's neue !

Greetz f-h  

Nichtspektakulär, aberimmerhin. Wenn ich mal zum Einstieg rate, sollte auch wasbeirumkommen.
Tschüssfürheute,zufaulfürdieLeertaste.

Gruss E.  

Hatte wenig Zeit, mich um meine kleinen Nasi-Perlen zu kümmern, hab aber eben mal die Zahlen vom 25.04. gelesen.

Gruss E.

Atrix Laboratories Reports 2003 First Quarter Financial Results Highlights: * Highest Quarterly Sales Revenue to Date * Net Sales and Royalties Increases 167% Over 1Q 2002 * Total Quarterly Revenue Increases to Over $9 Million  


FORT COLLINS, Colo., Apr 25, 2003 /PRNewswire-FirstCall via COMTEX/ -- Atrix
Laboratories, Inc. (Nasdaq: ATRX) today announced consolidated financial results
for the first quarter ended March 31, 2003.

For the quarter ending March 31, 2003, net sales and royalty revenue increased
167 percent to $3.2 million compared to $1.2 million in first quarter 2002. This
increase was primarily due to the recognition of $1.8 million in sales and
royalties from the Eligard(R) (leuprolide acetate for injectable suspension)
franchise as well as $0.5 million increase in sales of Atridox(R) (8.5%
doxycline) in Europe. The Eligard revenue included a full quarter of sales of
Eligard 7.5mg and Eligard 22.5mg and one month of sales of Eligard 30mg.

Total revenue increased 90 percent to $9.5 million compared to total revenue of
$5.0 million for the period ending March 31, 2002. Research and development
expenses increased 32 percent to $8.7 million for the period compared to $6.6
million for the three months ended March 31, 2002. The company continues to
focus on Phase III clinical studies for Eligard 45mg and Atrisone. Development
partners, including Fujisawa Healthcare Inc. and Sanofi-Synthelabo Inc.,
reimbursed approximately half of total R&D expenses. The net loss for the first
quarter 2003 was $3.0 million or $0.15 per share compared to a net loss for the
first quarter 2002 of $4.8 million or $0.24 per share.

"This quarter was marked by the approval and launch of the Eligard four-month
prostate cancer product, which now offers the entire Eligard product line the
opportunity to compete in the total market," said David R. Bethune, chairman and
chief executive officer at Atrix. Sanofi-Synthelabo has stated that they are
pleased with the uptake since the four-month product came on the market. We
expect Eligard sales to continue to exhibit strong growth in the second quarter
when we will have a full quarter of sales of all three strengths. Currently,
over 90 representatives are promoting Eligard. We are pleased that
Sanofi-Synthelabo continues to add resources to expand the number of urology
sales representatives."

Bethune continued, "We have made significant progress this quarter in the Phase
III studies for Atrisone(R) (5% dapsone) and the six-month Eligard product. In
fact, we are ahead of schedule on the clinical studies for Eligard 45mg and
working hard to make an earlier than planned New Drug Application submission of
this unique dosage form."

Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company focused
on advanced drug delivery. With five unique patented technologies, Atrix is
currently developing a diverse portfolio of proprietary products, including
oncology, pain management, and dermatology products. The company also partners
with large pharmaceutical and biotechnology companies to apply its proprietary
technologies to new chemical entities or to extend the patent life of existing
products. Additional information is available on the Atrix Laboratories, Inc.
website at http://www.atrixlabs.com.

Statements made in this press release may contain statements that qualify as
"forward-looking statements" under the Private Securities Litigation Reform Act
of 1995, including statements about the following topics: the company's
expectations for Eligard, Atrisone, and other products in development; the
company's expectation that their marketing partners will be able to successfully
market any products developed and/or approved; and its hopes for the future of
its business. The company is subject to certain risk factors that may cause
actual results to differ materially from anticipated results. Those risks
include, but are not limited to, the following: risks associated with product
demand, particularly the company's expectation of strong Eligard sales growth in
the second quarter; pricing, market acceptance of its current and proposed
products, changing economic conditions, risks in product and technology
development, the risk that a New Drug Application for Eligard 45mg might not be
submitted earlier than expected, and competition from other products and
treatments. For additional information about risk factors, please see the
reports filed by the company with the SEC, including the company's Annual Report
on Form 10-K for the year ended December 31, 2002 and the company's Quarterly
Report on Form 10-Q for the quarter ended March 31, 2003. The statements in this
press release are made as of today, based on information currently known to
management, and the company disclaims any duty to update such statements.







                 ATRIX LABORATORIES, INC. AND SUBSIDIARIES

                   CONSOLIDATED STATEMENTS OF OPERATIONS

              (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

                                (Unaudited)



                                             3 Months Ended    3 Months Ended

                                             March 31, 2003    March 31, 2002



   REVENUE:

     Net sales and royalties                     $3,219             $1,159

     Contract research and


 

Du Ungläubiger, Eski berät ganz gut.

Gruss E.

http://chart.bigcharts.com/bc3/quickchart/...48&mocktick=1&rand=8335"  

wie so oft von dir. ich hätte zum tiefstkurs kaufen können. der wert befindet sich leider nicht in meinem depot.

wenn du wieder mal so einen supertipp hast, bin ich dabei.

schönes wochenende